Evidence map›Paper›PMID 40308633›Full record

ArticleFrontiers in nutrition2025

Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy.

Yun Feng, Bingran Yu, Anxiao Liu, Chongpeng Cai, Changming Zhou, Tong Tong, Lu Wang, Qi Pan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yun Feng *Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Bingran Yu *Department of Pediatric Surgery, Shanghai Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai, China.
Anxiao Liu *Department of General Surgery, Shanghai Xuhui District Central Hospital, Shanghai, China.
Chongpeng CaiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Changming ZhouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tong TongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Lu WangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Qi PanDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths globally. Despite advances in targeted therapy and immunotherapy, survival rates for advanced HCC remain low. Combining hepatic artery infusion chemotherapy (HAIC) with systemic therapies shows potential, but identifying patients who benefit most is challenging. Body composition, including sarcopenia and myosteatosis, has been linked to cancer prognosis, but its role in HCC patients receiving HAIC with targeted and immunotherapies is unclear. Methods: This retrospective study analyzed 158 HCC patients treated with HAIC, tyrosine kinase inhibitors, and anti-PD-1 immunotherapy from January 2021 to October 2024. Body composition was assessed via CT scans at the L3 level, with sarcopenia defined by skeletal muscle index (SMI) and myosteatosis by skeletal muscle density (SMD). Progression-free survival (PFS) and overall survival (OS) were evaluated, and Cox regression analyses identified prognostic factors. Results: Sarcopenia cutoffs were 47.1 cm Conclusion: Sarcopenia and myosteatosis predict poor prognosis in HCC patients receiving HAIC with targeted therapy and immunotherapy. Sarcopenia is an independent risk factor for OS, highlighting the importance of body composition in prognosis. No significant associations were found between body composition and tumor response or PFS.

Indexed as

hepatic arterial infusion chemotherapyhepatocellular carcinomaimmunotherapymyosteatosissarcopeniatargeted therapy

Identifiers

PMID40308633
PMCPMC12040644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.